NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Soligenix's Heat-Stable Vaccine Platform and Recent Scientific Advancements
TL;DR
Soligenix's ThermoVax platform offers a competitive edge with heat-stable vaccines that can be stockpiled for rapid deployment during outbreaks, reducing logistical costs.
Soligenix's ThermoVax platform maintains vaccine structural integrity and immunogenicity for at least 24 months at 40°C using proprietary protein subunit technology and stabilization methods.
Soligenix's heat-stable vaccine technology improves global health equity by enabling reliable vaccine storage in remote areas without refrigeration, saving lives during outbreaks.
Soligenix developed vaccines that remain stable for years at scorching temperatures above 40°C, potentially transforming how we respond to deadly viruses like Ebola.
Found this article helpful?
Share it with your network and spread the knowledge!
The publication demonstrates long-term high-temperature stability of Soligenix's protein subunit vaccine platform for Ebola and Marburg-related viruses, showing the vaccines maintain structural integrity and immunogenicity after 24 months of storage at 40°C.
Heat-stable vaccines can remain stable when stored for extended periods at temperatures above 40°C, which could transform global outbreak response readiness by enabling vaccine deployment in regions without reliable refrigeration infrastructure.
Soligenix uses its proprietary ThermoVax® platform technology to stabilize vaccine formulations, allowing them to maintain structural integrity and immunogenicity under high-temperature conditions where unstabilized comparators degrade significantly.
The platform targets filoviruses including Ebola and Marburg-related viruses, with recent data specifically focusing on these pathogens.
The company's vaccine programs have been supported through U.S. government contracts and grants from BARDA (Biomedical Advanced Research and Development Authority), the National Institute of Allergy and Infectious Diseases (NIAID), and the Defense Threat Reduction Agency (DTRA).
Soligenix is also developing RiVax® for ricin toxin, CiVax™ for COVID-19 prevention, and has programs in its Specialized BioTherapeutics segment including HyBryte™ for cutaneous T-cell lymphoma and other inflammatory disease treatments.
The ThermoVax®-stabilized formulation maintained structural integrity and immunogenicity after extended high-temperature storage, while unstabilized comparators degraded significantly under identical conditions.
The company is a late-stage biopharmaceutical company with preclinical data showing successful long-term stability, and the technology has been expanded from an initial 12-month stability window to at least 24 months at 40°C.
For further information, visit the company's website at www.Soligenix.com or the company's newsroom at https://ibn.fm/SNGX.
Curated from InvestorBrandNetwork (IBN)
